Brain Training Shows Biological Impact on Alzheimer’s Markers, Study Finds

LONDON, UK – July 13, 2026 – In a potentially pivotal development for dementia prevention, new research presented today suggests that a specific form of digital brain training can directly influence the biological markers of Alzheimer’s disease. The findings, unveiled at the Alzheimer’s Association International Conference, indicate that the cognitive exercises in the BrainHQ app may reduce levels of beta amyloid in the blood, a primary indicator of the neurodegenerative disease.

This discovery, from a randomized controlled trial known as the ENACT Study, adds a significant biological dimension to the long-debated role of cognitive training in brain health. It suggests that targeted mental exercises may go beyond simple performance improvement, potentially altering the physiological pathways that lead to dementia.

A Trifecta of Evidence

The latest results stem from the ENACT (Elucidating the Necessary Active Components of Training) Study, which involved 53 participants who engaged in 20 hours of training. One group used BrainHQ’s “speed of processing” exercises, while a control group used common computer games like word searches. Researchers reported a significant improvement in the Aβ42/Aβ40 ratio—a key blood biomarker for Alzheimer’s—in the BrainHQ group. A higher ratio is associated with a lower amyloid burden in the brain.

“The ENACT Study researchers have run what we believe to be the first study to examine the relationship between brain training and levels of beta amyloid,” said Dr. Henry Mahncke, CEO of Posit Science, the company behind BrainHQ. He noted that the results, while perhaps surprising to some, fit into a larger, compelling narrative.

This study is the third major piece of evidence in under a year supporting the program's unique impact. It follows the 20-year follow-up of the landmark ACTIVE study, funded by the National Institutes of Health (NIH). Published in February, this massive trial of over 2,800 older adults found that just 23 hours of the same speed training, spread over three years, led to a 25% reduction in dementia diagnoses two decades later. Notably, other forms of cognitive training in the study, focused on memory and reasoning, did not produce a statistically significant reduction in dementia risk.

Furthermore, the NIH-funded INHANCE study, published last November, used advanced neuroimaging to show that 10 weeks of BrainHQ training could rejuvenate the brain’s production of acetylcholine. This vital neurotransmitter, crucial for attention and learning, is known to plummet in individuals with Alzheimer’s. The McGill University researchers reported the upregulation was equivalent to reversing about 10 years of age-related decline in the chemical's production.

“Taken together with the ACTIVE and INHANCE studies… they tell a very coherent and important story of a major evolution in our thinking about Alzheimer’s,” Dr. Mahncke stated. He explained that these studies show “the biological paths by which plasticity-based training can remodel the brain to slow and even reverse cognitive aging and offer some protection against dementia.”

Beyond Plaques and Tangles: A New Path for Prevention

The new findings arrive at a critical juncture in Alzheimer's research. For decades, the primary strategy has been pharmacological, focusing on clearing the amyloid plaques and tau tangles that are the disease's hallmarks. This has led to the recent approval of anti-amyloid antibody drugs like Lecanemab and Donanemab, which have shown a modest ability to slow cognitive decline.

However, these treatments are not without controversy. They carry significant risks, including Amyloid-Related Imaging Abnormalities (ARIA), which can manifest as potentially dangerous brain swelling or bleeding. An influential Cochrane review published in April 2026 concluded that despite showing statistically significant effects on amyloid levels, these drugs likely have “no clinically meaningful positive effects” for patients while substantially increasing health risks.

Against this backdrop, the prospect of a non-pharmacological intervention that can positively influence amyloid biomarkers without such side effects is gaining considerable attention. “The holy grail has always been an intervention that is safe, scalable, and effective,” commented one neurologist not involved in the study. “If cognitive training can be proven to alter the underlying biology of the disease, it represents a fundamental shift toward prevention and empowerment.”

Dr. Mahncke believes the collective evidence supports a new direction. “I believe a synthesis of these three recent breakthrough studies should further shift resources to dementia prevention and especially to the role of harnessing neuroplasticity to reduce inflammation, to upregulate neuromodulation, and to improve biological resilience of the brain as an organ.”

The Science of 'Speed Training' and a Cautious Consensus

While the term “brain training” is often met with skepticism, Posit Science argues its approach is fundamentally different. The company was co-founded by Dr. Michael Merzenich, a pioneering neuroscientist in the field of brain plasticity—the brain’s inherent ability to change and rewire itself. BrainHQ’s exercises are built on a “bottom-up” approach that focuses on improving the speed and accuracy of the brain's perceptual processing.

The “speed of processing” exercises at the heart of the ACTIVE and ENACT studies are adaptive, constantly adjusting their difficulty to push the user to process information faster and more accurately. This continuous challenge is believed to drive the neuroplastic changes that lead to broader cognitive benefits.

The scientific community at large remains cautious. Organizations like the Alzheimer's Society have stated there is not yet strong evidence that generic brain training activities prevent dementia. The industry has also been marred by controversy, with the U.S. Federal Trade Commission (FTC) taking action against companies like Lumosity for making unsubstantiated claims. It is a critical point of differentiation that Posit Science, which cites over 300 peer-reviewed studies on its technology, was not among the companies sued by the FTC.

The highly specific and positive results from the government-funded ACTIVE study, which isolated the benefits of “speed training,” lend significant weight to Posit Science's claims, setting its methodology apart from more generalized brain games.

From Lab to Living Room: Accessibility and Real-World Impact

With a growing body of evidence, the focus now shifts to real-world application. BrainHQ is delivered as a subscription-based app, making it accessible to anyone with a computer or mobile device. A personal subscription costs $14 per month or $96 for a year, with a limited selection of exercises available for free daily.

The company has already forged partnerships across diverse sectors, indicating a broad acceptance of its technology. BrainHQ is used by leading Medicare Advantage plans, medical centers, and even by elite organizations focused on peak performance, including the U.S. military and professional athletes.

The ENACT study also noted that biomarker changes varied by sex, aligning with a growing body of evidence that Alzheimer's-related therapies can affect men and women differently. This detail underscores the complexity of the disease and the need for personalized approaches to prevention.

As the scientific and medical communities continue to grapple with the complexities of Alzheimer’s, the convergence of technology and neuroplasticity offers a promising, accessible frontier. While no single study offers a definitive cure, the accumulating evidence suggests that structured, adaptive brain training may soon become a key tool in the global effort to build cognitive reserve and defend against dementia.